The British Journal of Cardiology

The BJC is a distinctive peer-reviewed journal that connects primary and secondary healthcare. It reaches a registered audience of 28,000 professional readers through both print and online formats, alongside 260,000 active online users. The print edition is published quarterly, and we also provide regular online updates. Our esteemed editorial board members are leaders in cardiometabolic medicine. The BJC is celebrated for delivering top-notch reviews, cutting-edge clinical research, and original articles in the field of cardiometabolic medicine, along with news coverage of global and UK congresses and meetings, as well as engaging podcasts. Additionally, BJC Learning offers extensive e-learning programs to enhance knowledge and skills.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#405200

United Kingdom

#47757

Health/Medicine

#200

Traffic sources

Monthly visitors

Articles

Grüntzig’s technique, relearnt

Oct 8, 2024 | bjcardio.co.uk | Pitt Lim

A quiet revolution without fanfare took place at a meeting, witnessed by over 1,000 people both in London and live streamed across the globe on 31 January 2024. It was unprecedented, going against received wisdom. That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent.
Subclavian venoplasty for device implantation in a district general hospital: a case series

Oct 8, 2024 | bjcardio.co.uk | Muhammad Usman Shah |Kelvin Lee |Hira Yousuf |David Morgan

Subclavian venoplasty is commonly performed for subclavian vein stenosis in patients with long-term dialysis lines or fistulae. Such stenosis may also occur in patients with previously implanted intra-cardiac devices. It poses a problem if a further device upgrade or implantation is planned as the stenosis restricts the advancement of leads. Venoplasty before device implantation may provide a feasible alternative to lead tunnelling or extraction, which have their limitations.
Lipoprotein(a) measurement - how, why and in whom?

Aug 1, 2024 | bjcardio.co.uk | Saleem Ansari |Jaimini Cegla

Genome-wide association and Mendelian randomisation studies have identified lipoprotein(a) (Lp[a]) as an emerging risk factor for calcific aortic stenosis and a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) in different ethnicities. Given that Lp(a) is predominantly genetically determined, blood levels are relatively stable over time.
Clinical utility of lipoprotein(a): an interventionist’s perspective

Aug 1, 2024 | bjcardio.co.uk | David Austin |Paul Williams |Ahai Luvai |Pyotr Telyuk

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease. Elevated Lp(a) concentrations in patients with ischaemic heart disease have been linked to higher rates of peri-procedural myocardial infarction (MI) during percutaneous coronary intervention (PCI).
Shortness of breath caused by a right ventricular metastasis: a case report

Jul 17, 2024 | bjcardio.co.uk | Muhammad Shahid |Suat Loo

Cardiac metastases normally reflect diffuse metastatic spread of the primary tumour and are rarely found in isolation. We present a case of a 71-year-old man with a history of completely resected high-grade spindle cell sarcoma of the left thigh, who presented with shortness of breath, and was found to have a large right ventricular mass, subsequently diagnosed as a metastasis of the prior sarcoma. It was deemed inoperable and incurable, and the patient was offered palliative chemotherapy.
Heart failure learning module 1: background, epidemiology, aetiology and pathophysiology

May 24, 2024 | bjcardio.co.uk | Jesus Esteban

Upon completing this module, participants should be better able to understand: The epidemiology of heart failure The burden of heart failure including its cost and findings from the National Heart Failure Audit The aetiology, precipitants and comorbidities of heart failure The various classifications of heart failure The syndromes and pathophysiology of heart failure Professor Andrew Clark, Chair in Clinical Cardiology, Hull York Medical School Dr Henry Savage, Specialist Registrar in...
Heartificial intelligence: in what ways will artificial intelligence lead to changes in cardiology over the next 10 years

Apr 16, 2024 | bjcardio.co.uk | Sam Brown

Artificial intelligence (AI) will revolutionise cardiology practices over the next decade, from optimising diagnostics to individualising treatment strategies. Moreover, it can play an important role in combating gender inequalities in cardiovascular disease outcomes. There is growing evidence that AI algorithms can match humans at echocardiography analysis, while also being able to extract subtle differences that the human eye cannot detect.
Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

Nov 29, 2023 | bjcardio.co.uk | Jacob George |Prashasthi Devaiah |Sava Handjiev

Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK.
Stent, balloon and hybrid in de novo PCI: could the whole be greater than the sum of its parts?

Nov 10, 2023 | bjcardio.co.uk | Pitt Lim

Andreas Grüntzig, an ardent angiologist crafted an indeflatable sausage-shaped dual-lumen balloon-catheter, designed its delivery to the heart, launched minimally invasive coronary intervention and taught by beaming live demonstration. Subsequent advances are just incremental tweaks and tinkers around this fully formed framework from 1978.
Mitral valve TEER in the UK: what you need to know as TEER becomes routinely available in the NHS

Oct 10, 2023 | bjcardio.co.uk | Jonathan Byrne |Daniel Blackman |Sam Dawkins |Robert Smith

Transcatheter edge-to-edge repair (TEER) was first performed in 2003, and is now established across the developed world as an effective, minimally invasive treatment option for patients with mitral regurgitation (MR). Multiple large registries have established the efficacy of mitral TEER in patients with primary or degenerative MR in whom surgery is considered prohibitive or high risk, while ongoing randomised-controlled trials will determine its role in younger and lower-risk patients.